Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02051634
Other study ID # IRB20140628
Secondary ID
Status Completed
Phase Phase 1
First received January 29, 2014
Last updated April 5, 2018
Start date October 2014
Est. completion date December 2016

Study information

Verified date April 2018
Source University of Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to explore the effects of fermented papaya preparation (FPP) on whole body inflammation, physical function, fatigue, and health-related quality of life. The investigators will conduct a double-blind, randomized, placebo-controlled pilot study on FPP in older adults. If FPP is found to have a beneficial impact on systematic inflammation in this study population (adults aged 70-100 years old), then this supplement may be a potential treatment option to combat aging.


Description:

All of the participants in this research study will be divided randomly into one of two groups: (1) a group taking fermented papaya preparation (FPP) for 8 weeks then taking placebo for 8 weeks or (2) a group taking placebo for 8 weeks then taking FPP for 8 weeks. Placebo sachets do not contain any treatment product. Participants will be assigned randomly to be in one of these two groups.

Participants will be asked to take study product for 8 weeks each, and participation in the study will last for a total of approximately 22 weeks. Participants will be asked to attend five study visits at the University of Florida's Institute on Aging - Clinical & Translational Research Building (IOA - CTRB): Screening Visit, Visit 1, Visit 2, Visit 3, and Visit 4. Visit 1 will take place approximately 30 days after the Screening Visit. Visit 2 will take place approximately 8 weeks after the Screening Visit. Visit 3 will take place approximately 16 weeks after the Screening Visit. Visit 4 will take place approximately 20 weeks after the Screening Visit. Participants will be asked to fast (i.e., no food or liquids except water) for 8 hours prior to all clinic visits. Each visit will take approximately 1.5 to 2 hours.

Participants will also be called weekly during the study to ask how they are feel and to find out and if they remembered to take all of their study product. Finally, investigators will call approximately two weeks after participants stop taking the study product to ask how they are feeling.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria:

- Body mass index > 25 and < 40 kg/m2;

- Willing and able to participate in all aspects of the study;

- Self-reported sedentary to moderately active lifestyle (<120 min aerobic activity/week);

- Self-reported ability to walk ΒΌ mile without the use of an assistive device (i.e., cane, walker, crutch);

- Mild to Moderate physical impairment (SPPB score 4-10);

- Not confined to a wheelchair;

- Mini Mental Status Exam score > 24;

- Able to swallow study product as directed.

Exclusion Criteria:

- Failure to give consent;

- Active treatment for cancer (< 3 years);

- Stroke (< 6 mo);

- Serious heart condition, peripheral vascular disease, coronary artery disease (myocardial infarction<6 mo), Class III, IV Congestive Heart Failure;

- Severe anemia (Hgb < 8.0 g/dL);

- Liver or renal disease;

- Diabetes;

- Severe osteoarthritis;

- Fracture in upper or lower extremity within the last 6 months;

- Upper or lower extremity amputation;

- Anticoagulant therapy (aspirin use is permitted);

- Parkinson's disease;

- Severe psychiatric disease or psychological disorder (e.g., severe depression, bi-polar disorder, schizophrenia) or current use of antipsychotics;

- Current use of anabolic medications (e.g., growth hormone or testosterone) or anticholinesterase inhibitor (i.e., Aricept);

- High amounts of physical activity (i.e., running, bicycling, etc.) > 120 min/week;

- Excessive alcohol use (>2 drinks per day);

- Use of tobacco products;

- Resting heart rate > 120 bpm;

- Blood pressure with Systolic > 160mmHg and Diastolic >90mmHg;

- History of significant head injury leading to cognitive impairments;

- Visual or hearing impairments that would interfere with testing;

- Current consumption of any dietary supplements containing resveratrol, quercetin, or P. cuspidatum, grape seed extract, or ginko biloba;

- Allergies to papaya or foods with similar compounds (i.e., banana, avocado, kiwi, chestnuts, hazel nuts)

- Allergy to latex;

- Participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment;

- Center for Epidemiological Studies - Depression Scale (CES-D) Score > 20.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fermented Papaya Preparation (FPP)
A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
Sugar Pill
A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.

Locations

Country Name City State
United States University of Florida Gainesville Florida

Sponsors (2)

Lead Sponsor Collaborator
University of Florida Osato Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Interleukin-6 (IL-6) will be tested at weeks 8 and 20 Blood test performed. Change from 8 weeks and 20 weeks
Primary Tumor necrosis factor-a (TNF-a) will be tested at weeks 8 and 20 Blood test will be performed. Change from 8 weeks and 20 weeks
Primary C - reactive protein (CRP) will be tested at weeks 8 and 20 Blood test will be performed. Change from 8 weeks and 20 weeks
Primary Myeloperoxidase (MPO) will be tested at weeks 8 and 20 Blood test will be performed. Change from 8 weeks and 20 weeks
Secondary Short Physical Performance Battery Physical function test to assess functional performance on different tasks including timed short distance walk, repeated chair stands, and a balance test. Change from 8 weeks and 20 weeks
Secondary 6 Minute Walk Test performed at weeks 8 and 20. The 6 Minute Walk tests functional walking endurance. Participants will be asked to walk at a comfortable pace for 6 minutes. Total distance completed, blood pressure, and pulse rate will be measured. Change from 8 weeks and 20 weeks
Secondary Health-related quality of life performed at weeks 8 and 20 RAND SF-36 Short Form Health Survey (SF-36) measures eight domains: physical functioning, role limitations due to physical health, role limitations due to emotional problems, vitality (energy/fatigue), emotional well being, bodily pain, social functioning, and general health perceptions. Change from 8 weeks and 20 weeks
Secondary Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) performed at weeks 8 and 20 FACIT-Fatigue is a measure of physical and functional consequences of fatigue, with lower scores indicating more fatigue. Change from 8 weeks and 20 weeks
Secondary Brief Fatigue Symptom Inventory (FSI) FSI is a measure of physical and functional consequences of fatigue. Change from 8 weeks and 20 weeks
Secondary Superoxide dismutases (SOD) tested at weeks 8 and 20. Blood test will be performed. Change from 8 weeks and 20 weeks
Secondary Glutathione Peroxidase tested at weeks 8 and 20. Blood test will be performed. Change from 8 weeks and 20 weeks
Secondary Total Antioxidant Capacity will be tested at weeks 8 and 20 Blood test will be performed. Change from 8 weeks and 20 weeks
Secondary Muscle tissue oxygenation tested at weeks 8 and 20 Participants will be asked to perform a leg extension endurance exercise with electrodes placed on their forehead and thigh. Change from 8 weeks and 20 weeks
Secondary Brain tissue oxygenation tested at weeks 8 and 20 Participants will complete a series of memory and thinking tasks while wearing electrodes on their head. The N-Back Test that measures working memory will be conducted for 10 minutes. Change from 8 weeks and 20 weeks
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A